Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 2/20 | 0.30 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL201004 | 0.94 | DUT (0.39) | DUTHIF1ATSHRFAAHTRPV1 | |
| SCHEMBL1008596 | 0.92 | TSHR (0.40) | DUTHIF1ATSHRFAAHTRPV1 | |
| SCHEMBL31240526 | 0.92 | TSHR (0.40) | DUTHIF1ATSHRFAAHTRPV1 | |
| SCHEMBL2917304 | 0.92 | TSHR (0.40) | DUTHIF1ATSHRFAAHTRPV1 | |
| SCHEMBL27241090 | 0.92 | TSHR (0.40) | DUTHIF1ATSHRFAAHTRPV1 | |
| SCHEMBL573170 | 0.87 | DUT (0.35) | DUT | |
| SCHEMBL20573300 | 0.81 | DUT (0.36) | DUTTSHR | |
| SCHEMBL27040101 | 0.81 | DUT (0.37) | DUT | |
| SCHEMBL4455945 | 0.81 | DUT (0.37) | DUTTSHR | |
| SCHEMBL29102792 | 0.80 | DUT (0.41) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 189 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119707725-A | Preparation method of 4-amino-5-hexenoate hydrochloride | 新乡学院 | 2025-03-28 | — | — | CN | claimed |
| CN-119463663-A | Corrosion-resistant stainless steel seamless steel pipe and manufacturing method thereof | 浙江邦诺钢管有限公司 | 2025-02-18 | — | — | CN | claimed |
| EP-0360246-A1 | 3-Oxiranyl benzoic acids and derivatives thereof | G.D. Searle & Co. (US) | 1990-03-28 | — | — | EP | claimed |
| EP-4104902-B1 | COMPOUNDS AND MEDICAMENTS USING SAME | IRIMAJIRI THERAPEUTICS INC (JP) | 2026-05-27 | — | — | EP | disclosed |
| US-20260137703-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECH LIMITED (GB) | 2026-05-21 | — | — | US | disclosed |
| US-12623988-B2 | Scaleable preparation of polyketides | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4658636-A1 | LIPID COMPOUNDS AND USES THEREOF | Pfizer Inc. (US) | 2025-12-10 | — | — | EP | disclosed |
| US-12473295-B2 | Substituted straight chain spiro derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2025-11-18 | — | — | US | disclosed |
| EP-4612148-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | Cancer Research Technology Limited (GB) | 2025-09-10 | — | — | EP | disclosed |
| EP-4577526-A1 | VHH ANTIBODY CONJUGATES | Abdera Therapeutics Inc. (US) | 2025-07-02 | — | — | EP | disclosed |
| WO-2025134066-A1 | IONIZABLE LIPIDS | BIONTECH DELIVERY TECHNOLOGIES GMBH (DE) | 2025-06-26 | — | — | WO | disclosed |
| US-20020007060-A1 | Reverse hydroxamate inhibitors of matrix metalloproteinases | DAVIDSEN STEVEN K (US) | 2002-01-17 | — | — | US | disclosed |
| EP-1159263-A1 | NOVEL SULFONAMIDE COMPOUNDS AND USES THEREOF | Merck & Co., Inc. (US) | 2001-12-05 | — | — | EP | disclosed |
| US-6294573-B1 | FOR THERAPY RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, OSTEOPENIAS SUCH AS OSTEOPOROSIS, PERIODONTITIS, GINGIVITIS, CORNEAL, EPIDERMAL OR GASTRIC ULCERATION, AND TUMOR GROWTH AND METASTASIS OR INVASION | ABBOTT LABORATORIES | 2001-09-25 | — | — | US | disclosed |
| WO-2000050391-A1 | NOVEL SULFONAMIDE COMPOUNDS AND USES THEREOF | MERCK & CO., INC. (US) | 2000-08-31 | — | — | WO | disclosed |
| US-5990326-A | AN ANTIINFLAMMATORY AGENT AS INHIBITORS OF LEUKOTRIENE HYDROLASE | G.D. SEARLE & CO. (US) | 1999-11-23 | — | — | US | disclosed |
| US-5411969-A | Antihyperlipidemic/antioxidant dihydroquinolines | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-05-02 | — | — | US | disclosed |
| US-5336771-A | Certain 3,4-dihydro-2H-pyrano[2,3-b]pyridines | PFIZER INC. (US) | 1994-08-09 | — | — | US | disclosed |
| EP-0360246-B1 | 3-Oxiranyl benzoic acids and derivatives thereof | SEARLE & CO (US) | 1994-03-30 | — | — | EP | disclosed |
| EP-0360246-A1 | 3-Oxiranyl benzoic acids and derivatives thereof | G.D. Searle & Co. (US) | 1990-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137703-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | EGFR, KRAS, O60361 | DUT 1465/4885HIF1A 3360/4885TSHR 590/4885 |
| US-12623988-B2 | Scaleable preparation of polyketides | SF3B5, RPS5, RPS25 | DUT 519/4885HIF1A 1199/4885TSHR 3595/4885 |
| US-12473295-B2 | Substituted straight chain spiro derivatives | MLLT1, MEN1, MLLT3 | DUT 4220/4885HIF1A 3180/4885TSHR 3952/4885 |
| US-20020007060-A1 | Reverse hydroxamate inhibitors of matrix metalloproteinases | MMP1, MMP9, MMP3 | DUT 536/4885HIF1A 608/4885TSHR 3628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.